1
|
Aguiar PM, Mori ALPM, Lima MGFD, Rossi MSPN, Nicoletti MA, Martins KOF, Lopes ALM, Coan TCM, Fugita OEH, Storpirtis S. The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil. BRAZ J PHARM SCI 2022. [DOI: 10.1590/s2175-97902021000219273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
2
|
Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H, Colecchia M, Delgado-Bolton R, Höckel M, Leonard K, Lövey J, Maroto P, Mastris K, Medeiros R, Naredi P, Oyen R, de Reijke T, Selby P, Saarto T, Valdagni R, Costa A, Poortmans P. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Crit Rev Oncol Hematol 2020; 148:102861. [PMID: 32151466 DOI: 10.1016/j.critrevonc.2019.102861] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 12/23/2019] [Accepted: 12/23/2019] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND ECCO Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give oncology teams, patients, policymakers and managers an overview of essential care throughout the patient journey. PROSTATE CANCER Prostate cancer is the second most common male cancer and has a wide variation in outcomes in Europe. It has complex diagnosis and treatment challenges, and is a major healthcare burden. Care must only be a carried out in prostate/urology cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.
Collapse
Affiliation(s)
- Maurizio Brausi
- European Association of Urology; Department of Urology, B. Ramazzini Hospital, Carpi-Modena, Italy
| | - Peter Hoskin
- European Society for Radiotherapy and Oncology (ESTRO); Mount Vernon Cancer Centre; University of Manchester, Manchester, United Kingdom
| | - Elisabeth Andritsch
- International Psycho-Oncology Society (IPOS); Clinical Department of Oncology, University Medical Centre of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Ian Banks
- European Cancer Organisation Patient Advisory Committee (ECCO PAC); European Men's Health Forum, Belgium
| | - Marc Beishon
- Cancer World, European School of Oncology (ESO), Milan, Italy.
| | - Helen Boyle
- International Society of Geriatric Oncology (SIOG); Department of Medical Oncology, Centre Léon-Bérard, Lyon, France
| | - Maurizio Colecchia
- European Society of Pathology (ESP); Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Roberto Delgado-Bolton
- European Association for Nuclear Medicine (EANM); Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), University of La Rioja, Logroño, La Rioja, Spain
| | - Michael Höckel
- European Society of Oncology Pharmacy (ESOP); Kliniken Kassel, Gesundheit Nordhessen Holding, Kassel, Germany
| | - Kay Leonard
- European Oncology Nursing Society (EONS); Saint Luke's Radiation Oncology Centre, St James's Hospital, Dublin, Ireland
| | - József Lövey
- Organisation of European Cancer Institutes (OECI); National Institute of Oncology, Budapest, Hungary
| | - Pablo Maroto
- European Organisation for Research and Treatment of Cancer (EORTC); Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ken Mastris
- European Cancer Organisation Patient Advisory Committee (ECCO PAC); Europa Uomo
| | - Rui Medeiros
- Association of European Cancer Leagues (ECL); Portuguese Cancer League, Instituto Portugues de Oncologia, Porto, Portugal
| | - Peter Naredi
- European Cancer Organisation (ECCO); Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Raymond Oyen
- European Society of Radiology (ESR); Department of Radiology, KU Leuven, Leuven, Belgium
| | - Theo de Reijke
- European Society of Surgical Oncology (ESSO); Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Peter Selby
- European Cancer Concord (ECC); Leeds Institute of Cancer and Pathology, University of Leeds; St James' University Hospital, Leeds, United Kingdom
| | - Tiina Saarto
- European Association for Palliative Care (EAPC); Palliative Care Center, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland
| | - Riccardo Valdagni
- European School of Oncology (ESO); Prostate Cancer Programme and Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | | |
Collapse
|
3
|
Noris Chiorda B, Zollo F, Magnani T, Badenchini F, Gatto L, Claps M, Macchi A, Andreoli L, Nicolai N, Villa S, Valdagni R. How to implement the requirements of a quality assurance system for prostate cancer. World J Urol 2019; 39:41-47. [PMID: 31776738 DOI: 10.1007/s00345-019-03024-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 11/15/2019] [Indexed: 12/26/2022] Open
Abstract
PURPOSE In 2003, the German Cancer Society (Deutsche Krebsgesellschaft, DKG) launched a certification program aimed at improving the quality of cancer care. The purpose of this article is to describe the experience of the Prostate Cancer Unit (PCU) at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, in the process towards DKG certification. METHODS In 2018, PCU decided to apply for certification by adopting DKG catalogue of requirements (CoR) and quality indicators. A multiprofessional working group was established with the aim of acting the necessary steps to meet DKG standards. RESULTS Our organizational setting (procedures, personnel) and activities were accurately analyzed, thus outlining strengths and weaknesses, and modified to comply with DKG CoR and indicators. As examples, (1) a quality management plan was developed; (2) measures were taken to strengthen the surgical expertise; (3) cases evaluated in weekly tumor boards were expanded to include surgical cases with pathological risk factors, metastatic, relapsed and castration-resistant patients; (4) a survey was added to the patient-dedicated initiatives already scheduled; (5) the TuDoc software became the tool to register all new cases of prostate cancer patients referred to PCU. CONCLUSIONS The process of certification requires many efforts but represents a unique opportunity of improving quality of care of prostate cancer patients, making it comparable on an international scale.
Collapse
Affiliation(s)
- Barbara Noris Chiorda
- Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Fabiana Zollo
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Tiziana Magnani
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
| | - Fabio Badenchini
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Lucia Gatto
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Melanie Claps
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Alberto Macchi
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Division of Oncologic Urologic Surgery, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Laure Andreoli
- Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Nicola Nicolai
- Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Division of Oncologic Urologic Surgery, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Sergio Villa
- Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Riccardo Valdagni
- Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Prostate Cancer Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.,Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
4
|
Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies’ agenda. TUMORI JOURNAL 2019; 105:161-167. [DOI: 10.1177/0300891618784789] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Introduction: The multidisciplinary management of oncologic patients is identified as the bottom line element of quality in tumor care. Methods: In 2015, 7 Italian scientific societies representing the specialists involved in the diagnosis and treatment of genitourinary tumors joined efforts in the Italian uro-oncologic multidisciplinary teams (MDTs) project. The aims were to promote the reorganization of genitourinary cancer care, switching to a multidisciplinary approach, reach a consensus on the core elements for the setup of MDTs in genitourinary oncology, and support health policy makers and managers in remodeling of the assistance and care of uro-oncologic patients on a national level. Results: The first activity was the setup of 5 working groups, given the task of exploring selected topics: general principles, organization of MDTs, minimal requirements, economic evaluation, and relations with authorities. The groups participated in the writing of a document that was approved by the scientific societies and published on their web sites. Moreover, a few items summarizing the extensive document were approved in the first MDT Consensus Conference held in Milan in December 2015. Conclusions: The experience of this initial phase led to the opening of the team to other professionals and societies, in line with a correct management of patients with genitourinary tumors, which need a multidisciplinary as well as a multiprofessional approach with emerging techniques and procedures, and with a new project work package on genitourinary paths of care and indicators.
Collapse
|
5
|
Wirth M, Fossati N, Albers P, Bangma C, Brausi M, Comperat E, Faithfull S, Gillessen S, Jereczek-Fossa BA, Mastris K, Mottet N, Müller SC, Pieters B, Ribal MJ, Sangar V, Schoots IG, Smelov V, Travado L, Valdagni R, Wesselmann S, Wiegel T, van Poppel H. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. Eur Urol 2019; 76:179-186. [PMID: 30799188 DOI: 10.1016/j.eururo.2019.01.033] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 01/22/2019] [Indexed: 02/02/2023]
Abstract
BACKGROUND High-quality management of prostate cancer is needed in the fields of clinics, research, and education. OBJECTIVE The objective of this project was to develop the concept of "European Prostate Cancer Centres of Excellence" (EPCCE), with the specific aim of identifying European centres characterised by high-quality cancer care, research, and education. DESIGN, SETTING, AND PARTICIPANTS A task force of experts aimed at identifying the general criteria to define the EPCCE. Discussion took place in conference calls and by e-mail from March 2017 to November 2017, and the final consensus meeting named "European Association of Urology (EAU) Prostate Cancer Centre Consensus Meeting" was held in Barcelona on November 16, 2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The required criteria were grouped into three main steps: (1) clinics, (2) research, and (3) education. A quality control approach for the three steps was defined. RESULTS AND LIMITATIONS The definition of EPCCE consisted of the following steps: (1) clinical step-five items were identified and classified as core team, associated services, multidisciplinary approach, diagnostic pathway, and therapeutic pathway; (2) research step-internal monitoring of outcomes was required; clinical data had to be collected through a prespecified database, clinical outcomes had to be periodically assessed, and prospective trials had to be conducted; (3) educational step-it consists of structured fellowship programmes of 1yr, including 6mo of research and 6mo of clinics; and (4) quality assurance and quality control procedures, related to the quality assessment of the previous three steps. A limitation of this project was that the definition of standards and items was mainly based on a consensus among experts rather than being an evidence-based process. CONCLUSIONS The EAU Prostate Cancer Centre Consensus Meeting defined the criteria for the identification of the EPCCE in the fields of clinics, research, and education. The inclusion of a quality control approach represents the novelty that supports the excellence of these centres. PATIENT SUMMARY A task force of experts defined the criteria for the identification of European Prostate Cancer Centres of Excellence, in order to certify the high-quality centres for prostate cancer management.
Collapse
Affiliation(s)
- Manfred Wirth
- European Association of Urology (EAU), Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
| | - Nicola Fossati
- European Association of Urology (EAU), Division of Oncology / Unit of Urology; IRCCS Ospedale San Raffaele, Milan, Italy.
| | - Peter Albers
- European Association of Urology (EAU), Department of Urology, University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Düsseldorf, Germany.
| | - Chris Bangma
- European Association of Urology (EAU), Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
| | - Maurizio Brausi
- EAU Section of Oncological Urology (ESOU)Department of Urology, B. Ramazzini Hospital, Carpi-Modena, Italy.
| | - Eva Comperat
- Service d'anatomie et cytologie pathologiques, hôpital Tenon, HUEP, Sorbonne université, Paris, France.
| | - Sara Faithfull
- European Association of Urology Nurses (EAUN), School of Health Sciences, Faculty of Health & Medical Sciences, Duke of Kent Building, University of Surrey,Surrey, UK.
| | - Silke Gillessen
- European Organisation for Research and Treatment of Cancer (EORTC), Manchester Cancer Research Centre, Manchester, UK.
| | - Barbara Alicja Jereczek-Fossa
- European Society for Radiotherapy and Oncology (ESTRO), Department of Oncology and Hemato-oncology, University of Milan, Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
| | | | - Nicolas Mottet
- European Association of Urology (EAU), Department of Urology, University Hospital, St. Etienne, France.
| | | | - Bradley Pieters
- European Society for Radiotherapy and Oncology (ESTRO), Amsterdam University Medical Centers / University of Amsterdam, Amsterdam, The Netherlands.
| | - Maria J Ribal
- European Urological Scholarship Programme (EUSP), Uro-Oncology Unit. Hospital Clínic. University of Barcelona, Spain.
| | - Vijay Sangar
- European Association of Urology (EAU), The Christie NHS Foundation Trust & Manchester University Hospital NHS Foundation Trust, Manchester, UK.
| | - Ivo G Schoots
- European Society of Uro Radiology (ESUR), Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
| | - Vitaly Smelov
- Prevention and Implementation Group, Section of Early Detection and Prevention, International Agency for Research on Cancer (IARC), World Health Organization (WHO).
| | - Luzia Travado
- International Psycho-Oncology Society (IPOS), Psycho-oncology, Champalimaud Clinical and Research Center, Champalimaud Foundation, Lisbon, Portugal.
| | - Riccardo Valdagni
- European School of Oncology (ESO), University of Milan, Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Radiation Oncology, Milano, Italy.
| | | | - Thomas Wiegel
- European Society for Radiotherapy and Oncology (ESTRO) Milan, Italy.
| | - Hendrik van Poppel
- European Association of Urology (EAU), Dept Urology, University Hospital KU Leuven, Belgium.
| |
Collapse
|
6
|
Abstract
Urologists should be aware of the importance of staying updated with the latest advances in medical research, chasing complications after surgery, being aware of postoperative results, building up a multidisciplinary team, and designing randomised trials for relevant research questions. Taken together, these key elements would allow for optimisation of patients' outcomes in everyday clinical practice.
Collapse
Affiliation(s)
- Francesco Montorsi
- Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
| |
Collapse
|
7
|
Fersino S, Arcangeli S, Jereczek-Fossa BA, D’Angelillo R, Bertoni F, D’Agostino GR, Triggiani L, Corvò R, Magrini SM, Alongi F. GUROPA survey: genito-urinary radiation oncology prescription attitudes. Radiol Med 2018; 123:879-884. [DOI: 10.1007/s11547-018-0918-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 07/03/2018] [Indexed: 01/02/2023]
|
8
|
De Vincentis G, Monari F, Baldari S, Salgarello M, Frantellizzi V, Salvi E, Reale L, Napolitano S, Conti G, Cortesi E. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. Future Oncol 2018; 14:2821-2832. [PMID: 29905090 DOI: 10.2217/fon-2018-0318] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM To describe the journey of patients with metastatic castration-resistant prostate cancer (mCRPC) in treatment with radium-223. METHODS A multiperspective analysis was performed using narrative medicine in four Italian centers. RESULTS The substantial impact of mCRPC on quality of life through all phases of the disease was described. After an initial lack of awareness of the disease or denial of its effects, symptoms of pain, fatigue and side effects often led to sadness, fear and loneliness. The majority underwent radium-223 therapy positively, restoring their quality of life and routine activities. CONCLUSION Using narrative medicine, the importance of a patient-centered approach in the pathway of care for patients with mCRPC through all the stages of the disease was highlighted.
Collapse
Affiliation(s)
- Giuseppe De Vincentis
- Department of Radiological Sciences, Oncology & Anatomo-Pathology, Sapienza - University of Rome, Rome, Italy
| | - Fabio Monari
- UO Metabolic Radiation Unit Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Emilia-Romagna, Italy
| | - Sergio Baldari
- Department of Biomedical Sciences & Morphological & Functional Images, Università degli Studi di Messina, Messina, Italy
| | - Matteo Salgarello
- Division of Nuclear Medicine, Sacro Cuore - Don Calabria Hospital, Negraro (VR), Italy
| | - Viviana Frantellizzi
- Department of Radiological Sciences, Oncology & Anatomo-Pathology, Sapienza - University of Rome, Rome, Italy
| | - Elisabetta Salvi
- UO Metabolic Radiation Unit Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Emilia-Romagna, Italy
| | - Luigi Reale
- ISTUD Foundation, Healthcare Area, Milan, Italy
| | | | - Giario Conti
- Department of Urology, Sant'Anna Hospital, Como, Italy.,Segretario Nazionale della Società Italiana di Urologia Oncologica (SIUrO), Bologna, Italy
| | - Enrico Cortesi
- Medical Oncology, Policlinico Umberto I, Sapienza, University of Rome, Rome, Italy
| |
Collapse
|
9
|
Horgan S, O'Donovan A. The Impact of Exercise during Radiation Therapy for Prostate Cancer on Fatigue and Quality of Life: A Systematic Review and Meta-analysis. J Med Imaging Radiat Sci 2018; 49:207-219. [DOI: 10.1016/j.jmir.2018.02.056] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 02/23/2018] [Accepted: 02/23/2018] [Indexed: 12/14/2022]
|
10
|
The role of individual characteristics in predicting decisional conflict for patients with prostate cancer (PCa): preliminary results. CURRENT PSYCHOLOGY 2017. [DOI: 10.1007/s12144-017-9753-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Towards sustainable cancer care: Reducing inefficiencies, improving outcomes—A policy report from the All.Can initiative. J Cancer Policy 2017. [DOI: 10.1016/j.jcpo.2017.05.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
12
|
Lamb AD, Thompson S, Kinsella N, Gerbitz I, Chapman E, Putt L, Bennett S, Thankappannair V, Geoghegan L, Wright N, Stirton-Croft A, Nixon P, Styling A, Whitney D, Hodgson L, Punt L, Longmore J, Carter M, Petch B, Rimmer Y, Russell S, Hughes-Davies L, Mazhar D, Shah NC, Gnanapragasam VJ, Doble A, Bratt O, Kastner C. Aiming for a holistic integrated service for men diagnosed with prostate cancer - Definitions of standards and skill sets for nurses and allied healthcare professionals. Eur J Oncol Nurs 2017; 29:31-38. [PMID: 28720263 DOI: 10.1016/j.ejon.2017.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2016] [Revised: 04/19/2017] [Accepted: 04/20/2017] [Indexed: 11/16/2022]
Abstract
PURPOSE To establish a comprehensive set of recommendations for the service structure and skill set of nurses and allied healthcare professionals in prostate cancer care. METHODS Using components of formal consensus methodology, a 30-member multidisciplinary panel produced 53 items for discussion relating to the provision of care for prostate cancer patients by specialist nurses and allied healthcare professionals. Items were developed by two rounds of email correspondence in which, first, items were generated and, second, items refined to form the basis of a consensus meeting which constituted the third round of review. The fourth and final round was an email review of the consensus output. RESULTS The panel agreed on 33 items that were appropriate for recommendations to be made. These items were grouped under categories of "Environment" and "Patient Pathway" and included comments on training, leadership, communication and quality assessment as well as specific items related to prostate diagnosis clinics, radical treatment clinics and follow-up survivor groups. CONCLUSIONS Specialist nurses and allied healthcare professionals play a vital role alongside urologists and oncologists to provide care to men with prostate cancer and their families. We present a set of standards and consensus recommendations for the roles and skill-set required for these practitioners to provide gold-standard prostate cancer care. These recommendations could form the basis for development of comprehensive integrated prostate cancer pathways in prostate cancer centres as well as providing guidance for any units treating men with prostate cancer.
Collapse
Affiliation(s)
- Alastair D Lamb
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Sue Thompson
- Peterborough City Hospital, Peterborough, Cambridgeshire, UK
| | | | - Ingmar Gerbitz
- Martini-Klinik, Martinistraße 52, 20246 Hamburg, Germany
| | - Elaine Chapman
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Lisa Putt
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Sophie Bennett
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | | | - Lisa Geoghegan
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Naomi Wright
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | | | - Penny Nixon
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Andrew Styling
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Diane Whitney
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Lindsay Hodgson
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Lisa Punt
- Maggies Wallace, Long Road, Cambridge, UK
| | - Jenny Longmore
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Mike Carter
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK; Patient representatives
| | - Bill Petch
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK; Patient representatives
| | - Yvonne Rimmer
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Simon Russell
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Luke Hughes-Davies
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Danish Mazhar
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Nimish C Shah
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | | | - Andrew Doble
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK
| | - Ola Bratt
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK; Department of Translational Medicine, Division of Urological Cancer, Lund University, Sweden
| | - Christof Kastner
- CamPARI Clinic, Cancer Directorate, Addenbrooke's Hospital, Cambridge, UK.
| |
Collapse
|
13
|
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. Crit Rev Oncol Hematol 2017; 113:43-51. [PMID: 28427521 DOI: 10.1016/j.critrevonc.2017.03.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Revised: 03/03/2017] [Accepted: 03/03/2017] [Indexed: 01/22/2023] Open
Abstract
Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC.
Collapse
|
14
|
Madaan S, Reekhaye A. NICE prostate cancer quality standards. JOURNAL OF CLINICAL UROLOGY 2016. [DOI: 10.1177/2051415816642694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Prostate cancer is the most common cancer in men in the United Kingdom. Over 42,000 men are diagnosed with prostate cancer every year. In June 2015, the National Institute for Health and Care Excellence (NICE) finally published five key statements regarding prostate cancer care. The quality standards are mostly derived from the NICE prostate cancer guidelines. In this article, we discuss the development process by the NICE Advisory Committee and highlight the five key priorities proposed by NICE to drive quality improvements in patient safety, patient experience and clinical effectiveness. We also discuss areas for potential improvement to improve the standard of care for men with prostate cancer.
Collapse
Affiliation(s)
- Sanjeev Madaan
- Department of Urology and Nephrology, Darent Valley Hospital, UK
| | | |
Collapse
|
15
|
OECI accreditation at Veneto Institute of Oncology IOV -- IRCCS, general framework and multidisciplinary approach. TUMORI JOURNAL 2015; 101 Suppl 1:S38-41. [PMID: 27096271 DOI: 10.5301/tj.5000459] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/02/2015] [Indexed: 11/20/2022]
Abstract
The aim of this article is to describe the accreditation process of the Veneto Institute of Oncology (IOV-IRCCS) according to the Organisation of European Cancer Institutes (OECI) model, with particular reference to the standards for the multidisciplinary approach. Through the analysis of the process and the activities of each multidisciplinary team (MDT) and the development, at a regional level, of diagnostic, therapeutic, and care pathways (PDTA), all the necessary steps to meet the OECI standards have been determined. Adjustment is ongoing. We are working on the inclusion of the MDT registration forms in the electronic medical records and on the possibility to extend the OECI model to the MDT not based at IOV, but participated in by IOV professionals. The sarcoma MDT has achieved results demonstrating that the OECI framework has allowed the professionals involved in the multidisciplinary meeting to systematically share the clinical information of the patient, who can benefit from better continuity of care. The model has also provided greater clarity in the management of patients who are enrolled in clinical trials and deviate from Guide Lines (GL)/PDTA. The accreditation process according to the OECI model has added value to the IOV's already well-developed multidisciplinary activities.
Collapse
|
16
|
Steffens J, Kranz J, Albers P. Verbesserte Behandlung des Prostatakarzinoms in zertifizierten Zentren. Urologe A 2015; 54:1515-6. [DOI: 10.1007/s00120-015-3835-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Bombardieri E, Evangelista L, Ceresoli GL, Boccardo F. Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment. Eur J Nucl Med Mol Imaging 2015; 43:5-7. [PMID: 26381776 DOI: 10.1007/s00259-015-3189-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 09/01/2015] [Indexed: 11/25/2022]
Affiliation(s)
- Emilio Bombardieri
- Nuclear Medicine Department, Cliniche Humanitas Gavazzeni, Via Gavazzeni 21, 24125, Bergamo, Italy.
| | - L Evangelista
- Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy
| | - G L Ceresoli
- Medical Oncology Department, Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - F Boccardo
- Academic Unit of Medical Oncology, IRCCS AOU San Martino-IST (San Martino University Hospital and National Cancer Research Institute), Genova, Italy
| |
Collapse
|